MedTrace Logo

Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.

NCT02585388 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-09-06

No results posted yet for this study

Summary

The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment

Conditions

Interventions

DRUG

Vinorelbine

Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued

DRUG

Letrozole

Lestrozole at 2,5 mg every day , per oral

DRUG

Anastrozole

Anastrozole at 1 mg every day, per oral

Sponsors & Collaborators

  • Pierre Fabre Laboratories

    collaborator INDUSTRY

  • ARCAGY/ GINECO GROUP

    lead OTHER

Principal Investigators

  • Pierre-Etienne HEUDEL, MD · Centre Leon Berard

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
95 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-23
Primary Completion
2017-05-15
Completion
2017-05-15

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02585388 on ClinicalTrials.gov